{
    "clinical_study": {
        "@rank": "40080", 
        "arm_group": [
            {
                "arm_group_label": "Part A, Group 1 - 10^8 pu", 
                "arm_group_type": "Experimental", 
                "description": "Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^8 particle units."
            }, 
            {
                "arm_group_label": "Part A, Group 2 - 10^9 pu", 
                "arm_group_type": "Experimental", 
                "description": "Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^9 particle units."
            }, 
            {
                "arm_group_label": "Part A, Group 3 - 10^10 pu", 
                "arm_group_type": "Experimental", 
                "description": "Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^10 particle units."
            }, 
            {
                "arm_group_label": "Part B, Group 1 - AdVEGF-All6A+", 
                "arm_group_type": "Experimental", 
                "description": "Part B  (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A."
            }, 
            {
                "arm_group_label": "Part B, Group 2 - AdNull placebo", 
                "arm_group_type": "Experimental", 
                "description": "Part B  (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector."
            }
        ], 
        "brief_summary": {
            "textblock": "The proposed Phase I/II clinical trial will be used to determine the safety and toxicity of\n      direct administration of the vector AdVEGF-All6A+ to the ischemic myocardium and to generate\n      preliminary evidence regarding whether direct administration of AdVEGF-All6A+ to the\n      ischemic myocardium will induce growth of collateral blood vessels and improve cardiac\n      function. This is a three-part, multinational/multi-center, placebo controlled study."
        }, 
        "brief_title": "Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery", 
        "completion_date": {
            "#text": "January 2028", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females, age 18 to 90\n\n          -  Demonstrable reversible left ventricular ischemia in viable myocardium as assessed by\n             ST segment/T wave abnormalities detected by exercise testing with echocardiogram\n             prior to and following the exercise test\n\n          -  Individuals who have coronary artery disease (CAD)  but have angina refractory to\n             medical therapy\n\n          -  Individuals who experience angina class III-IV\n\n          -  Individuals who are not considered to be eligible for coronary artery bypass surgery,\n             stents, or angioplasty, because of the lack of suitable target lesions\n\n          -  Individuals must be medically capable of undergoing open thoracotomy\n\n          -  Individuals must have neutralizing anti-adenovirus serotype 5 titer \u2264160; this\n             criteria is based on the knowledge that some individuals have high anti Ad5\n             neutralizing antibody titer which may limit efficacy\n\n          -  Hematocrit >30%\n\n          -  WBC <10,000\n\n          -  Normal prothrombin, partial thromboplastin time (excluding IV heparin therapy)\n\n          -  Normal liver-related serum parameters\n\n          -  Glomerular filtration rate (GFR) > 30 ml/min\n\n          -  No evidence of active infection of any types, including adenovirus, hepatitis virus\n             (A, B or C) or human immunodeficiency virus\n\n          -  No evidence of central nervous system, major psychiatric, musculoskeletal or immune\n             disorder\n\n          -  No allergy to the vehicle used to suspend the virus or contrast materials used in\n             radiographic procedures\n\n          -  Fertile or infertile individuals; it will be recommended that fertile individuals\n             utilize barrier birth control measures to prevent pregnancy during and for 2 months\n             following the administration of the vector\n\n          -  Individuals not receiving experimental medications or participating in another\n             experimental protocol for at least 4 weeks prior to entry to the study.\n\n          -  Individuals must be able to exercise for at least 90 seconds but no more than 8 min\n             on an Asymptomatic Cardiac Ischemia Pilot protocol exercise treadmill test (Stone, PH\n             et al. Am. J. Cardiol. 1997; 80: 1395-1401) while exhibiting angina with concurrent 1\n             mm horizontal or downsloping ST-segment depression\n\n          -  The study individual must be able to undergo the procedures in the protocol\n\n          -  Willingness to participate in the study\n\n          -  Capable of providing informed consent\n\n        Exclusion Criteria:\n\n          -  Individuals who do not meet the inclusion criteria will be unable to participate in\n             the protocol\n\n          -  Individuals in whom participation in the study would compromise the normal care and\n             expected progression of their disease\n\n          -  Individuals receiving corticosteroids or other immunosuppressive medications\n\n          -  Individuals with uncontrolled diabetes\n\n          -  Diabetic individuals with significantly abnormal ophthalmologic exam relevant to the\n             protocol as assessed by protocol physicians\n\n          -  Individuals with hypercholesterolemia (LDL above 190 mg/dl or total cholesterol above\n             240 mg/dl)\n\n          -  Body mass index >35\n\n          -  Recent (<6 wk) cerebral vascular accident\n\n          -  Recent (<6 wk) transmural myocardial infarction\n\n          -  Evidence of infection defined by elevated white blood cell count, temperature\n             >38.5\u00baC, infiltrate on chest x-ray\n\n          -  Unable to undergo cardiac MRI with gadolinium contrast\n\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values 2.5\n             greater than normal limits\n\n          -  Severe chronic obstructive pulmonary disease as demonstrated by either room air\n             arterial PO2 <60 mm Hg or PCO2 >50 mm Hg, or abnormal pulmonary function tests (FEV1\n             <1 L/sec)\n\n          -  Cardiac transplantation\n\n          -  Electrocardiograph abnormalities that would interfere with ST-segment analysis\n\n          -  Untreated malignant ventricular arrhythmia\n\n          -  Valvular heart disease requiring surgical intervention\n\n          -  Preoperative congestive heart failure (New York Heart Association Function Class III\n             or IV or ejection fraction (EF) <25%\n\n          -  Pregnancy or currently lactating\n\n          -  Prior participation in cardiac gene and/or cell therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757223", 
            "org_study_id": "1204012330", 
            "secondary_id": "1201-1145"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A, Group 1 - 10^8 pu", 
                    "Part A, Group 2 - 10^9 pu", 
                    "Part A, Group 3 - 10^10 pu", 
                    "Part B, Group 1 - AdVEGF-All6A+"
                ], 
                "description": "We will administer AdVEGF-All6A+,  an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.", 
                "intervention_name": "AdVEGF-All6A+", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Part B, Group 2 - AdNull placebo", 
                "description": "AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.", 
                "intervention_name": "AdNull", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Endothelial Growth Factors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Diffuse Coronary Artery Disease (CAD)", 
        "lastchanged_date": "December 20, 2012", 
        "number_of_arms": "5", 
        "official_title": "Phase I/II Study, Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor to the Ischemic Myocardium of Individuals With Diffuse Coronary Artery Disease Via Minimally Invasive Surgery", 
        "overall_contact": {
            "email": "chollman@med.cornell.edu", 
            "last_name": "Charleen Hollmann, RN, BSN, MPA, PhD, CCRP", 
            "phone": "646-962-2672"
        }, 
        "overall_contact_backup": {
            "email": "mey2003@med.cornell.edu", 
            "last_name": "Mary E. Yeotsas, CCRC", 
            "phone": "646-962-4563"
        }, 
        "overall_official": {
            "affiliation": "Weill Medical College of Cornell University", 
            "last_name": "Ronald Crystal, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Recombinant DNA Advisory Committee", 
                "United States: Data Safety Monitoring Board", 
                "United States: Clinical & Translational Science Center", 
                "United States: Institutional Biosafety Committee", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to 1 mm ST depression during exercise-stress testing", 
            "safety_issue": "No", 
            "time_frame": "3 mos (Part A); 6 mos (Part B)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757223"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess segmental wall motion in treated territories", 
                "measure": "Exercise-stress echocardiogram", 
                "safety_issue": "No", 
                "time_frame": "Twice before vector administration at -30 days and -15 days (\u00b1 5 days), and will be repeated at day 90 post-vector for Part A and day 90 and 180 post-vector for Part B"
            }, 
            {
                "measure": "Angina, as measured by the Canadian Cardiovascular Society Functional Classification of Angina Pectoris", 
                "safety_issue": "No", 
                "time_frame": "Twice pre-vector administration at -30 days and -15 days, and repeated at 30 and 90 days post-vector for Part A and at 30, 90 and 180 days post-vector for Part B"
            }, 
            {
                "description": "To assess segmental wall motion and perfusion in treated territories", 
                "measure": "Cardiac MRI +/- adenosine stress", 
                "safety_issue": "No", 
                "time_frame": "Once pre-vector and repeated at 90 days post vector for Part A, and 180 days post-vector for Part B"
            }
        ], 
        "source": "Weill Medical College of Cornell University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Weill Medical College of Cornell University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}